Overview of Creval

The following overview provides a clear definition and classification of the medicine Creval, strictly focused on its identity and general purpose.

Property	Description
Active ingredient	Valdecoxib
Form	Tablet (Oral dosage form)
Pharmacological class	Selective COX-2 Inhibitor (NSAID)
General purpose	Relief of pain and inflammation
Origin	Synthetic

What Type of Medicine is Creval (Valdecoxib)?

Creval is a prescription-only, synthetic medication containing the active substance Valdecoxib, which is broadly classified as a Non-Steroidal Anti-inflammatory Drug (NSAID). It belongs to the specific subclass of NSAIDs known as selective Cyclooxygenase-2 (COX-2) inhibitors, or Coxibs. This class of medicine is primarily utilized for its strong anti-inflammatory and analgesic effects. The drug is designed to mitigate the physical symptoms of inflammation throughout the body, such as providing relief for patients experiencing musculoskeletal discomfort.

Composition and Form: What is Valdecoxib?

The active compound, Valdecoxib, is structurally defined as a sulfonamide derivative and an isoxazole chemical entity. Creval is manufactured as a single-ingredient product, formulated for oral dosage in the form of a tablet. This preparation ensures the stability of the compound and its effective absorption via the gastrointestinal tract. Although Creval is one trade name, the active ingredient Valdecoxib is the same compound found in other brands like Bextra and Valdyn, sharing its fundamental composition and therapeutic class.

What is the General Purpose of a Selective COX-2 Inhibitor?

The general purpose of Creval is to relieve symptoms of pain and inflammation by using a targeted mechanism. Valdecoxib works by specifically blocking the COX-2 enzyme, which is activated at sites of injury and synthesizes pain- and inflammation-causing messengers called prostaglandins. This action provides the drug's core benefit by reducing the swelling and discomfort associated with inflammatory processes, making it clinically recognized for its anti-inflammatory efficacy.

What side effects are possible with Creval?

Official Safety Profile of Creval

The safety information for Creval is structured based on formal government regulatory guidelines, classifying adverse reactions according to their frequency and the specific body system or organ they affect.

Adverse Reactions and Frequency

Adverse reactions are formally classified using standardized terms. The primary method of reporting is by System Organ Class (SOC), which groups side effects (known as undesirable effects) based on the affected body system (e.g., Gastrointestinal disorders, Nervous system disorders).

Reported frequencies in regulatory documents often use standard categories derived from clinical trial data, such as:

Very Common (ge 1/10)
Common (ge 1/100 to < 1/10)
Uncommon
Rare
Very Rare

Serious Risks and Safety Limitations

The official labeling highlights Serious Adverse Reactions (SARs), which are defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization, or results in persistent or significant disability. The document also details Contraindications, which are specific situations where the medicine is strictly prohibited from use due to an unacceptable level of risk.

Specific Warnings and Precautions are noted in the regulatory text, drawing attention to risks that require particular care during treatment. These may include the potential for Fibrosing Colonopathy (associated with high doses) or Hyperuricemia (increased uric acid levels), or the need to monitor for Hypersensitivity Reactions.

Regulatory Monitoring and Specific Populations

Regulatory authorities mandate continuous safety surveillance through a Pharmacovigilance process or a Risk Management Plan (RMP). This ongoing monitoring aims to detect new or rare safety concerns after the medicine is made available to the public. Additionally, specific safety considerations, such as the potential for Embryo-Fetal Toxicity or data on use during pregnancy and in the paediatric population, are addressed if relevant, based on the findings presented to the government body.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Creval (Valdecoxib) typically presents with symptoms limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain. The most common physiological systems affected include the gastrointestinal and central nervous systems. Although rare, more severe manifestations documented in regulatory sources can include gastrointestinal bleeding, acute renal failure, respiratory depression, coma, and hypertension.

Immediate medical attention must be sought for any suspected overdose situation. Management is strictly symptomatic and supportive, as no specific antidote is known for Valdecoxib. Official instructions advise that interventions such as forced diuresis or hemodialysis are unlikely to be effective due to the drug's high protein binding. Procedural measures that may be considered include the use of activated charcoal or gastric lavage if initiated soon after ingestion.

Certain patient considerations are documented: patients with moderate hepatic impairment may experience significantly increased plasma concentrations of the drug. Furthermore, the elderly population has been noted to potentially have a greater incidence of edema and hypertension at higher doses. Discontinuation and urgent medical review are mandated at the first sign of a skin rash or other indication of hypersensitivity.

Therapeutic Uses of Creval

What Creval Treats: Main Uses and Benefits

Creval (Valdecoxib) is applied across domains where additional symptomatic support is needed, primarily to provide symptomatic relief and supportive therapeutic benefit against pain and inflammation. It is used in clinical settings for conditions characterized by periods of heightened symptoms, including Osteoarthritis, Adult Rheumatoid Arthritis, and Primary Dysmenorrhea.

It is commonly used to help manage the persistent joint pain, swelling, and stiffness associated with chronic conditions, as well as the intense manifestations of postoperative pain and acute cramping discomfort. The symptomatic relief offered may help patients cope more steadily with symptom fluctuations and supports day-to-day comfort, particularly during phases when symptoms become more noticeable.

Quick Fact: Relief for Musculoskeletal Discomfort
Creval is considered relevant when short-term symptomatic assistance is needed for acute episodes, or for chronic management of symptoms that create noticeable physiological strain on the joints.

Eligibility and Restrictions for Use

Who Can and Cannot Use Creval?

Creval (Valdecoxib) eligibility is strictly defined by regulatory documents, focusing on populations for whom use is contraindicated or restricted.

Contraindicated Populations (Must Not Use)

Condition/Status	Regulatory Status
Allergy to Valdecoxib or Sulfonamides	Contraindicated
NSAID-induced Allergic Reactions	Contraindicated
Severe Heart Failure (NYHA Class III-IV)	Contraindicated
Severe Hepatic Dysfunction (Child-Pugh 10)	Contraindicated
Active GI Bleeding or Peptic Ulcers	Contraindicated
Third Trimester of Pregnancy	Contraindicated
Breastfeeding	Contraindicated
Post-Coronary Artery Bypass Graft (CABG) Surgery Pain	Contraindicated

Age and Conditional Use

Creval is approved for use in adults (18 years and older). Use is not recommended in pediatric patients (under 18 years) due to insufficient data. Conditional use is required for patients with moderate hepatic impairment (Child-Pugh 7-9) and those with impaired renal function, where use should proceed with caution. The medicine is not recommended for women who are attempting to conceive.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Creval (Valdecoxib) interacts with a range of co-administered medicinal products, with official restrictions based on pharmacokinetic changes and pharmacodynamic risk amplification.

Officially documented contraindications include use in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other non-aspirin Non-Steroidal Anti-inflammatory Drugs (NSAIDs) or analgesic doses of aspirin is not recommended due to increased risk of serious gastrointestinal toxicity.

Pharmacokinetic Interactions are documented when Creval is taken with substances that affect its metabolic clearance. Co-administration with the CYP2C9 inhibitor Fluconazole results in a significant increase in Valdecoxib plasma exposure (AUC). Conversely, Phenytoin (a CYP3A4 inducer) is documented to decrease Valdecoxib exposure. Valdecoxib itself increases the exposure of drugs like Warfarin, Diazepam, and Oral Contraceptives.

Pharmacodynamic Interactions require careful monitoring. Co-administration with Warfarin increases the risk of serious bleeding events, necessitating close monitoring of anticoagulant activity. The antihypertensive effect of ACE Inhibitors, ARBs, and Diuretics may be diminished. Additionally, combining Creval with these antihypertensives or with Cyclosporin/Tacrolimus carries an increased risk of renal function deterioration, especially in the elderly or volume-depleted populations. An increased risk of gastrointestinal bleeding is noted with alcohol and SSRIs/SNRIs.

Mechanism of Action

Dual Adrenergic Receptor Antagonism

Creval functions as a non-selective adrenergic receptor antagonist by binding to Beta-1, Beta-2, and Alpha-1 receptors on the surface of various cells. This interaction prevents the agonistic binding of endogenous catecholamines, such as norepinephrine and epinephrine, thereby interrupting sympathetic signaling. In the cardiac tissues, this antagonism modifies the molecular pathway governing myocardial contractility and heart rate, resulting in a reduction in the rate and force of contraction, which modulates cardiac output.

Vascular and Cellular Modulation

The Alpha-1 receptor blockade specifically targets the smooth muscle of blood vessels, initiating a cascade that leads to vasodilation. This physiological consequence decreases peripheral vascular resistance. Independent of receptor binding, the molecule possesses an intrinsic ability to act as a scavenger of free radicals. This secondary action influences the cellular environment by modulating the cellular redox state through the suppression of reactive oxygen species.

Dosage and Administration Information

How to Use Creval (Valdecoxib)

Creval is a medication administered orally as a tablet, available in 10 mg and 20 mg strengths. The fundamental principle guiding its use is to utilize the lowest effective dose for the shortest duration consistent with the required treatment protocol.

The dosing schedule is strictly determined by the specific condition being addressed. The tablets may be taken with or without food; administration alongside a high-fat meal may delay the time to peak concentration.

Condition	Recommended Dosing Regimen
Chronic Use (e.g., Osteoarthritis, Rheumatoid Arthritis)	10 mg once daily. The maximum recommended dose is 20 mg once daily.
Acute Use (e.g., Primary Dysmenorrhea)	40 mg once daily, taken as required. An additional 40 mg dose may be taken on the first day if needed, but subsequent daily doses should not exceed 40 mg.

Population-Specific Administration Rules

Dosage adjustments are required for certain patient profiles. Treatment must be introduced at the lowest recommended dose (10 mg once daily) for older adults (ge 65 years) who weigh less than 50 kg, and for patients with moderate hepatic impairment or those concurrently receiving known CYP inhibitors. Creval is not intended for use in individuals under 18 years of age.

If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. Patients must not double the dose to compensate for a missed administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Creval

Evidence from Clinical Trials for Osteoarthritis

The primary research base for Creval was used in studies exploring the signs and symptoms of Osteoarthritis (OA). The core evidence comes from several large Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms, typically comparing the medicine to a placebo (an inactive substance) and sometimes to other comparator drugs. The studies included adults diagnosed with active OA, focusing on those with discomfort in the knee or hip.

Researchers mainly monitored patient-reported outcomes describing perceived discomfort. These included standardized measures like pain intensity scales and the WOMAC index, which tracks outcomes reflecting daily functioning or activity level, such as stiffness and physical limitations. Studies report how symptoms evolved in the observed populations during the short-term treatment periods evaluated. This evidence contributes to the broader evidence landscape by characterizing symptom evolution in the observed populations.

Evidence from Clinical Trials for Adult Rheumatoid Arthritis

Research examined Creval in studies exploring how symptoms change over time for individuals with Adult Rheumatoid Arthritis (RA). These research efforts primarily consisted of Randomized Controlled Trials applied in research contexts involving fluctuating or unstable symptoms. The studies included adults with active RA, and research examined outcomes related to systemic or functional imbalance.

To track how the condition evolved, studies monitored changes in patient-reported outcomes as well as specific medical measures, such as the ACR indices, which assess disease activity. Findings describe patterns observed in the studies regarding changes in swelling, joint tenderness, and overall functional status over the observation periods. This research provides insight into short-term changes in conditions characterized by fluctuating or episodic manifestations.

Evidence from Acute Pain Studies (Postoperative Pain and Dysmenorrhea)

Research for Creval also studied outcomes related to physical discomfort, including its use in conditions involving periods of heightened symptoms such as postoperative pain (e.g., following dental or orthopedic surgery) and Primary Dysmenorrhea (menstrual cramping). These studies primarily used short-term RCTs, often involving a single dose or a few days of treatment.

The main focus of this research was on outcomes describing episodic or acute changes. Studies monitored the intensity of pain, time to use of rescue medication, and whether patients needed rescue pain medication. Research highlights changes measured during the study period, indicating that Creval was studied in research exploring short-term changes in patient-reported outcomes describing perceived discomfort during these acute episodes.

Long-Term Research and Follow-up Durations

Research has explored outcomes related to physical discomfort over defined time intervals. For chronic conditions like Osteoarthritis and Rheumatoid Arthritis, regulators rely on research that includes both studies focused on short-term symptom patterns and longer follow-up for comparative data. The initial, high-quality RCTs that measured changes in symptoms generally had follow-up durations that were limited to a few months.

This means that long-term effects are not fully established by the core trials. While some studies observed responses over intermediate-term periods, the durability of any observed symptomatic patterns and their evolution over years is an area where data are still emerging. Consequently, long-term outcomes are not well characterized, and research continues to contribute to the broader evidence landscape as more time passes.

Evidence in Specific Patient Populations

Most core clinical studies focused on general adult populations meeting specific, defined criteria for their condition (OA or RA). Research was evaluated in patients within certain age ranges. Evidence is limited regarding how the medicine works in very specific groups, particularly those with complex or co-existing medical conditions that were typically excluded from the primary trials.

While studies included older adults with arthritis, research primarily focuses on adults, and data for certain groups, such as those with highly active or rapidly progressing disease, remain insufficient. Evidence is also limited for pediatric patients. Research does not determine whether an individual will respond similarly to the group patterns described in the studies, especially if their health profile differs significantly from the populations studied in the RCTs.

Research Gaps and What Remains Uncertain

The overall evidence base provides insight into short-term changes in symptom intensity or variability for the studied conditions. However, evidence quality varies across studies, and several areas require further research.

Long-term effects are not fully established, meaning the research provides limited information for long-term outcomes or how treatment affects conditions over many years.
Subgroup findings are uncertain, as initial trials often exclude patients with certain high-risk factors or complex comorbidities, meaning the research applies only to the populations studied.
Data for certain groups remain insufficient, particularly for understanding potential physiological strain or stress over extended periods of use in high-risk individuals.
Comparative evidence is lacking for some of the newer therapeutic options now available.

These limitations mean that while the research describes patterns observed in the studies, it also highlights what is known—and what is still uncertain—about the evidence base for Creval.

Key Studies & References

FDA Alert on Bextra (valdecoxib) Withdrawal and Safety Concerns (Public Health Advisory)

Frequently Asked Questions (FAQ)

Common questions about Creval (FAQ)

Q: How quickly can someone expect Creval to start working?

Official drug information states that the active ingredient in Creval reaches its maximal plasma concentrations in approximately 3 hours after the tablet is taken. This measurement reflects the time required for the greatest amount of the medicine to be circulating in the bloodstream, which is a factor in how soon its effects may be observed.

Q: How long does the effect of one dose of Creval usually last?

According to official data, the elimination half-life of the active ingredient is approximately 8.11 hours. The half-life is a scientific measure that describes how long it takes for half of the medicine to be naturally processed and cleared from the body. This characteristic is considered by healthcare professionals when determining appropriate dosing intervals.

Q: Are there any specific vitamins or supplements that should not be taken with Creval?

Regulatory warnings focus on substances that interact with certain liver enzymes, such as CYP2C9, which the body uses to process Creval. If another substance inhibits this enzyme, it may alter the drug's overall exposure, which can affect the risk of side effects. Official guidance generally focuses on medicinal interactions, not an exhaustive list of every vitamin or supplement.

Q: Does Creval cause weight gain or weight loss?

Studies cited in official product information indicate that weight gain has been reported as an adverse reaction in clinical data. This effect is classified in regulatory documents as common, meaning it has been observed in clinical studies in up to 1 out of every 100 people who used the medication.

Q: Is Creval a controlled substance?

Creval's active ingredient is categorized as a Non-Steroidal Anti-inflammatory Drug, or NSAID. Regulatory authorities have determined that this medicine is not scheduled as a controlled substance under the U.S. Controlled Substances Act (CSA) guidelines.

Q: Does Creval affect sleep patterns?

According to official safety data, effects on sleep patterns have been reported in individuals taking the medicine. Both sleepiness (somnolence) and problems sleeping (insomnia) are listed as common side effects in official safety data, observed in clinical studies in up to 1 out of every 100 people.

Q: Are there any known issues with Creval and operating machinery?

Regulatory information notes that side effects affecting the nervous system, such as dizziness and headache, have been reported in some patients. These types of effects have been noted in official product information as potentially impairing the ability to perform tasks requiring alertness, such as operating machinery.

Q: What is the purpose of the 'inactive ingredients' listed in Creval?

Inactive ingredients are components included in the tablet formulation for several non-medicinal purposes. They help to ensure the proper form and stability of the tablet, assist in the manufacturing process, and contribute to its effective absorption by the body. These ingredients do not have a therapeutic effect.

Q: How does Creval affect lab test results?

Official warnings mention that the medicine may potentially lead to abnormalities in routine lab tests that check liver function or kidney function. For individuals taking the medicine over a long period, regulatory documents note that monitoring may be indicated.

Q: What are some common reasons people stop taking Creval?

Regulatory authorities indicated that the active ingredient was voluntarily withdrawn from the market in 2005 due to safety concerns. These concerns included a possible increased risk of serious cardiovascular events, such as heart attack and stroke, and reports of severe, unpredictable skin reactions.

Q: Has Creval been recalled or had any major safety warnings recently?

Official public health advisories confirm that the medicine containing this active ingredient was voluntarily withdrawn from the U.S. and European markets in April 2005. This action was taken due to safety concerns identified through ongoing surveillance.

Q: What information is usually found in a Creval patient information leaflet?

The patient information leaflet is a required document that summarizes information based on regulatory approval. It typically includes details on what the medicine is, its approved uses, important warnings and side effects, and practical information such as dosing instructions and proper storage.

How should Creval be stored and disposed of?

How to Store and Dispose of Creval (Valdecoxib)

The storage and disposal of Creval tablets must adhere strictly to regulatory conditions to maintain product integrity and safety.

Official Storage Requirements

Condition	Requirement
Temperature	Store at 25°C (77°F); permitted excursions between 15 C and 30 C (59 F and 86 F).
Protection	Keep in a closed container and protect from light and moisture; keep from freezing.
Child Safety	Store the medicine out of the sight and reach of children.
Stability	Labeled shelf life is 30 to 36 months, depending on the packaging type.

Disposal Instructions

Unused or expired Creval must not be flushed down the toilet or poured into a sink. Disposal must follow government-established guidelines, typically through an authorized drug take-back program. Alternatively, the tablets can be mixed with an undesirable substance (e.g., dirt) in a sealed bag for disposal in household trash, after removing all personal information from the label. Releases to the environment should be avoided.

Creval